Drug
BION-1301
BION-1301 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (66.7%)
Phase 31 (33.3%)
Trials by Status
active_not_recruiting133%
completed133%
terminated133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_3
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938
completedphase_1
Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects
NCT05508204
terminatedphase_1
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
NCT03340883
Clinical Trials (3)
Showing 3 of 3 trials
NCT05852938Phase 3
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05508204Phase 1
Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects
NCT03340883Phase 1
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3